drugset / Trial / NCT00795613

Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)

NCT00795613

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this multicenter clinical trial is to assess the clinical impact of dose intensification performed very early during treatment in a subset of poor prognosis, advanced-stage Hodgkin Lymphoma patients, defined as PET-positive after two courses of conventional adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.

Timeline

Start
2008-06
Primary completion
2014-11
Completion
2015-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bleomycin Unknown 10 mg/m2 Intravenous
Subject Bleomycin Unknown 10000 unknown Intravenous
Subject Cyclophosphamide Other / unclassified 650 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 1250 mg/m2 Intravenous
Subject Dacarbazine Small molecule 375 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 35 mg/m2 Intravenous
Subject Etoposide Small molecule 100 mg/m2 Intravenous
Subject Etoposide Small molecule 200 mg/m2 Intravenous
Subject Prednisone Other / unclassified 40 mg/m2 Oral
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Vinblastine Small molecule 6 mg/m2 Intravenous
Subject Vincristine Small molecule 1.4 mg/m2 Intravenous
Subject procarbazine Small molecule 100 mg/m2 Oral
Background G-CSF Unknown 300 ug Subcutaneous

Indications